KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.

Viktor Grünwald, Rana R McKay, Tomas Buchler, Masatoshi Eto, Se Hoon Park, Toshio Takagi, Sylvie Zanetta, Daniel Keizman, Cristina Suárez, Sylvie Négrier, Jae Lyun Lee, Daniele Santini, Jens Bedke, Michael Staehler, Christian Kollmannsberger, Toni K Choueiri, Robert J Motzer, Joseph E Burgents, Ran Xie, Chinyere E Okpara, Thomas Powles

Int J Cancer 156(7) 1326-1335

PMID39739622
PMCIDPMC11789451
DOI10.1002/ijc.35288
发表日期2024-12-31
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图。
摘要

摘要

Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc analysis of tumor response data based on baseline metastatic characteristics of patients who received lenvatinib plus pembrolizumab versus sunitinib, at the final overall survival analysis time point of CLEAR (cutoff: July 31, 2022). Treatment-naïve adults with aRCC were randomized to: lenvatinib (20 mg PO QD in 21-day cycles) plus pembrolizumab (n = 355; 200 mg IV Q3W); lenvatinib plus everolimus (not reported here); or sunitinib (n = 357; 50 mg PO QD; 4 weeks on/2 weeks off). The most common (lenvatinib plus pembrolizumab; sunitinib, respectively) metastatic site was lung (71.0%; 63.9%), followed by lymph node (45.6%; 43.7%), bone (22.5%; 24.9%), and liver (17.7%; 19.6%). Across treatment arms, ≥65% had two or more metastatic organs/sites involved, >80% of patients had nontarget lesions, and ~45% had baseline sums of diameters of target lesions ≥60 mm. Lenvatinib plus pembrolizumab demonstrated greater progression-free survival, objective response rate, and duration of response versus sunitinib across evaluable subgroups regardless of site or size of baseline metastasis or number of metastatic sites at baseline. Overall survival generally trended to favor lenvatinib plus pembrolizumab versus sunitinib; and tumor shrinkage was greater across sites (lung, lymph node, liver, and bone) for patients in the lenvatinib-plus-pembrolizumab arm versus the sunitinib arm. These results further support lenvatinib plus pembrolizumab as a standard-of-care in patients with aRCC regardless of site or size of baseline metastasis or the number of metastatic sites.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Progression‐free survival by independent imaging review per RECIST v1.1 (A), and overall survival (B) in subgroups of the lenvatinib plus pembrolizumab versus sunitinib arms. Data for all subgroups in (A) were derived based on information obtained from the independent imaging review. Median PFS and OS were estimated with Kaplan–Meier method, and 95% CI was constructed with a generalized Brookmeyer and Crowley method. Stratification factors were geographic region (Region 1: Western Europe and North America, Region 2: Rest of the world) and MSKCC prognostic groups (favorable, intermediate, and poor risk) in the interactive voice/web response system. If a stratification factor was within its own subgroup, this factor was excluded from stratified analysis. a Patients who died or had progressive disease (for PFS); patients who died (for OS); b Hazard ratio was based on a Cox proportional hazards model including treatment group as a factor; Efron method was used for ties. Stratification factors were geographic region (Region 1: Western Europe and North America, Region 2: Rest of the world) and MSKCC prognostic groups (favorable, intermediate, and poor risk) in the interactive voice/web response system; c The number of patients with baseline brain metastasis was very low. The data should be interpreted cautiously, considering this. CI, confidence interval; DOR, duration of response; HR, hazard ratio; L + P, lenvatinib plus pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version v1.1; S, sunitinib.
非 KM Figure
FIGURE 2Tumor response and duration of response by independent imaging review per RECIST v1.1 in subgroups of the lenvatinib plus pembrolizumab versus sunitinib arms. a The number of patients with baseline brain metastasis was very low. The data should be interpreted cautiously, considering this; b Odds ratios were calculated using the Cochran–Mantel–Haenszel method, stratified by interactive voice/web response system stratification factors; c Median DOR is for all responders. Medians were estimated with Kaplan–Meier product‐limit method and 95% CIs were constructed with a generalized Brookmeyer and Crowley method. Derivation of data was based on information obtained from the independent imaging review. Stratification factors were geographic region (Region 1: Western Europe and North America, Region 2: Rest of the world) and MSKCC prognostic groups (favorable, intermediate, and poor risk) in the interactive voice/web response system. If a stratification factor was within its own subgroup, this factor was excluded from stratified analysis. Arrows indicate 95% CI values that fall outside the scale of the graph. CI, confidence interval; DOR, duration of response; L + P, lenvatinib plus pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not estimable; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version v1.1; S, sunitinib.
非 KM Figure
FIGURE 3Percentage change in the sum of diameters of target lesions in the lung (A), lymph nodes (B), liver (C), and bone (D) from baseline to postbaseline nadir. These figures include patients (m) with baseline and at least 1 postbaseline target lesion assessment in the respective organ per independent imaging review.
非 KM Figure